Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

Cited In for PubMed (Select 9145677)

1.

Effect of Next-Generation Exome Sequencing Depth for Discovery of Diagnostic Variants.

Kim K, Seong MW, Chung WH, Park SS, Leem S, Park W, Kim J, Lee K, Park RW, Kim N.

Genomics Inform. 2015 Jun;13(2):31-9. doi: 10.5808/GI.2015.13.2.31. Epub 2015 Jun 30.

2.

Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.

Jagsi R, Griffith KA, Kurian AW, Morrow M, Hamilton AS, Graff JJ, Katz SJ, Hawley ST.

J Clin Oncol. 2015 May 10;33(14):1584-91. doi: 10.1200/JCO.2014.58.5885. Epub 2015 Apr 6.

PMID:
25847940
3.

Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.

Kinney AY, Butler KM, Schwartz MD, Mandelblatt JS, Boucher KM, Pappas LM, Gammon A, Kohlmann W, Edwards SL, Stroup AM, Buys SS, Flores KG, Campo RA.

J Natl Cancer Inst. 2014 Nov 5;106(12). pii: dju328. doi: 10.1093/jnci/dju328. Print 2014 Dec.

PMID:
25376862
4.

Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population.

van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK.

Eur J Hum Genet. 2015 May;23(5):588-95. doi: 10.1038/ejhg.2014.161. Epub 2014 Aug 20.

5.

Frailty Models for Familial Risk with Application to Breast Cancer.

Gorfine M, Hsu L, Parmigiani G.

J Am Stat Assoc. 2013 Dec 1;108(504):1205-1215.

6.

Clinical interpretation and implications of whole-genome sequencing.

Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, Chaib H, Merker JD, Goldfeder RL, Enns GM, David SP, Pakdaman N, Ormond KE, Caleshu C, Kingham K, Klein TE, Whirl-Carrillo M, Sakamoto K, Wheeler MT, Butte AJ, Ford JM, Boxer L, Ioannidis JP, Yeung AC, Altman RB, Assimes TL, Snyder M, Ashley EA, Quertermous T.

JAMA. 2014 Mar 12;311(10):1035-45. doi: 10.1001/jama.2014.1717.

7.

Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer.

Kim H, Choi DH.

J Breast Cancer. 2013 Dec;16(4):357-65. doi: 10.4048/jbc.2013.16.4.357. Epub 2013 Dec 31. Review.

8.

Hereditary cancer risk assessment: essential tools for a better approach.

Gomy I, Estevez Diz Mdel P.

Hered Cancer Clin Pract. 2013 Oct 28;11(1):16. doi: 10.1186/1897-4287-11-16.

9.

Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer.

Keshavarzi F, Noughani AE, Ayoubian M, Zeinali S.

Iran J Public Health. 2011;40(2):57-66. Epub 2011 Jun 30.

10.

Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.

Beristain E, Ibáñez B, Vergara I, Martínez-Bouzas C, Guerra I, Tejada MI.

J Community Genet. 2010 Jun;1(2):91-9. doi: 10.1007/s12687-010-0014-0. Epub 2010 Aug 9.

11.

Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.

Kwong A, Wong CH, Suen DT, Co M, Kurian AW, West DW, Ford JM.

World J Surg. 2012 Apr;36(4):702-13. doi: 10.1007/s00268-011-1406-y.

12.

Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K.

CA Cancer J Clin. 2011 Sep-Oct;61(5):327-59. doi: 10.3322/caac.20128. Epub 2011 Aug 19. Review.

13.

Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil.

Palmero EI, Caleffi M, Schüler-Faccini L, Roth FL, Kalakun L, Netto CB, Skonieski G, Giacomazzi J, Weber B, Giugliani R, Camey SA, Ashton-Prolla P.

Genet Mol Biol. 2009 Jul;32(3):447-55. doi: 10.1590/S1415-47572009005000058. Epub 2009 Sep 1.

14.

Ethnic, racial and cultural identity and perceived benefits and barriers related to genetic testing for breast cancer among at-risk women of African descent in New York City.

Sussner KM, Edwards TA, Thompson HS, Jandorf L, Kwate NO, Forman A, Brown K, Kapil-Pair N, Bovbjerg DH, Schwartz MD, Valdimarsdottir HB.

Public Health Genomics. 2011;14(6):356-70. doi: 10.1159/000325263. Epub 2011 May 3.

15.

The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes.

Kim D, Jung W, Koo JS.

J Korean Med Sci. 2011 Mar;26(3):352-9. doi: 10.3346/jkms.2011.26.3.352. Epub 2011 Feb 25.

16.

Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.

Wevers MR, Ausems MG, Verhoef S, Bleiker EM, Hahn DE, Hogervorst FB, van der Luijt RB, Valdimarsdottir HB, van Hillegersberg R, Rutgers EJ, Aaronson NK.

BMC Cancer. 2011 Jan 10;11:6. doi: 10.1186/1471-2407-11-6.

17.

Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study.

Lindor NM, Johnson KJ, Harvey H, Shane Pankratz V, Domchek SM, Hunt K, Wilson M, Cathie Smith M, Couch F.

Fam Cancer. 2010 Dec;9(4):495-502. doi: 10.1007/s10689-010-9348-3.

18.

Derepression of HMGA2 via removal of ZBRK1/BRCA1/CtIP complex enhances mammary tumorigenesis.

Ahmed KM, Tsai CY, Lee WH.

J Biol Chem. 2010 Feb 12;285(7):4464-71. doi: 10.1074/jbc.M109.062265. Epub 2009 Dec 10.

19.

Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection.

van Harssel JJ, van Roozendaal CE, Detisch Y, Brandão RD, Paulussen AD, Zeegers M, Blok MJ, Gómez García EB.

Fam Cancer. 2010 Jun;9(2):193-201. doi: 10.1007/s10689-009-9305-1.

20.

Novel breast tissue feature strongly associated with risk of breast cancer.

McKian KP, Reynolds CA, Visscher DW, Nassar A, Radisky DC, Vierkant RA, Degnim AC, Boughey JC, Ghosh K, Anderson SS, Minot D, Caudill JL, Vachon CM, Frost MH, Pankratz VS, Hartmann LC.

J Clin Oncol. 2009 Dec 10;27(35):5893-8. doi: 10.1200/JCO.2008.21.5079. Epub 2009 Oct 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk